89,623 Shares in Immunome, Inc. $IMNM Acquired by Legal & General Group Plc

Legal & General Group Plc bought a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 89,623 shares of the company’s stock, valued at approximately $1,899,000. Legal & General Group Plc owned about 0.08% of Immunome at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Creative Planning boosted its stake in shares of Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after purchasing an additional 935 shares during the period. Allworth Financial LP bought a new position in Immunome in the 2nd quarter worth $25,000. California State Teachers Retirement System lifted its position in Immunome by 1.8% during the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after purchasing an additional 1,167 shares in the last quarter. Finally, Assetmark Inc. lifted its position in Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after purchasing an additional 1,442 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

NASDAQ IMNM opened at $26.76 on Monday. The stock’s 50 day moving average is $24.96 and its 200 day moving average is $22.58. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $30.06. The stock has a market cap of $3.04 billion, a PE ratio of -10.58 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, analysts forecast that Immunome, Inc. will post -2.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IMNM has been the topic of several recent research reports. Wedbush raised their price objective on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Truist Financial increased their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.64.

Insider Buying and Selling at Immunome

In other news, insider Kinney Horn sold 90,616 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the transaction, the insider owned 50,366 shares in the company, valued at $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of Immunome stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the completion of the sale, the insider directly owned 15,805 shares in the company, valued at $357,509.10. This trade represents a 77.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 682,310 shares of company stock worth $15,675,566. Insiders own 7.21% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.